|
Market Closed -
Other stock markets
|
After hours 07:55:16 pm | |||
| 27.70 USD | +8.67% |
|
27.58 | -0.45% |
| Dec. 04 | AI's rise stirs excitement, sparks job worries | RE |
| Dec. 02 | Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11:00 AM |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenues | 803M | 18.47B | 19.26B | 6.67B | 3.11B | ||||
Other Revenues, Total | - | - | - | 177M | 127M | ||||
Total Revenues | 803M | 18.47B | 19.26B | 6.85B | 3.24B | ||||
Cost of Goods Sold, Total | 1.38B | 4.61B | 8.71B | 9.54B | 6.01B | ||||
Gross Profit | -575M | 13.86B | 10.55B | -2.69B | -2.77B | ||||
Selling General & Admin Expenses, Total | 188M | 567M | 1.13B | 1.55B | 1.17B | ||||
Other Operating Expenses, Total | 188M | 567M | 1.13B | 1.55B | 1.17B | ||||
Operating Income | -763M | 13.3B | 9.42B | -4.24B | -3.94B | ||||
Interest Expense, Total | -9.89M | -18M | -29M | -38M | -24M | ||||
Interest And Investment Income | 24.72M | 18M | 200M | 421M | 425M | ||||
Net Interest Expenses | 14.83M | 0 | 171M | 383M | 401M | ||||
Currency Exchange Gains (Loss) | - | -8M | 48M | - | - | ||||
Other Non Operating Income (Expenses) | 2.74M | -4M | -44M | -14M | -7M | ||||
EBT, Excl. Unusual Items | -746M | 13.28B | 9.6B | -3.87B | -3.55B | ||||
Gain (Loss) On Sale Of Investments | 1.3M | 1M | -20M | -72M | -56M | ||||
Gain (Loss) On Sale Of Assets | -238K | - | - | - | - | ||||
EBT, Incl. Unusual Items | -745M | 13.28B | 9.58B | -3.94B | -3.61B | ||||
Income Tax Expense | 2.55M | 1.08B | 1.21B | 772M | -46M | ||||
Earnings From Continuing Operations | -747M | 12.2B | 8.36B | -4.71B | -3.56B | ||||
Net Income to Company | -747M | 12.2B | 8.36B | -4.71B | -3.56B | ||||
Net Income - (IS) | -747M | 12.2B | 8.36B | -4.71B | -3.56B | ||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | ||||
Net Income to Common Incl Extra Items | -747M | 12.2B | 8.36B | -4.71B | -3.56B | ||||
Net Income to Common Excl. Extra Items | -747M | 12.2B | 8.36B | -4.71B | -3.56B | ||||
Per Share Items | |||||||||
Net EPS - Basic | -1.96 | 30.28 | 21.22 | -12.34 | -9.27 | ||||
Basic EPS - Continuing Operations | -1.96 | 30.28 | 21.22 | -12.34 | -9.27 | ||||
Basic Weighted Average Shares Outstanding | 381M | 403M | 394M | 382M | 384M | ||||
Net EPS - Diluted | -1.96 | 28.29 | 20.12 | -12.34 | -9.28 | ||||
Diluted EPS - Continuing Operations | -1.96 | 28.29 | 20.12 | -12.34 | -9.28 | ||||
Diluted Weighted Average Shares Outstanding | 381M | 431M | 416M | 382M | 384M | ||||
Normalized Basic EPS | -1.22 | 20.6 | 15.22 | -6.33 | -5.78 | ||||
Normalized Diluted EPS | -1.22 | 19.26 | 14.42 | -6.33 | -5.78 | ||||
Payout Ratio | - | - | - | - | - | ||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | ||||
Supplemental Items | |||||||||
EBITDA | -732M | 13.53B | 9.77B | -3.62B | -3.76B | ||||
EBITA | -763M | 13.3B | 9.42B | -4.24B | -3.94B | ||||
EBIT | -763M | 13.3B | 9.42B | -4.24B | -3.94B | ||||
EBITDAR | -696M | 13.7B | 9.98B | -3.42B | -3.6B | ||||
Total Revenues (As Reported) | 803M | 18.47B | 19.26B | 6.85B | 3.24B | ||||
Effective Tax Rate - (Ratio) | -0.34 | 8.15 | 12.67 | -19.58 | 1.28 | ||||
Current Domestic Taxes | 32K | 1.34B | 1.73B | -153M | -58M | ||||
Current Foreign Taxes | 2.52M | 40M | 57M | 24M | 13M | ||||
Total Current Taxes | 2.55M | 1.38B | 1.79B | -129M | -45M | ||||
Deferred Domestic Taxes | - | -294M | -576M | 896M | - | ||||
Deferred Foreign Taxes | - | -2M | -2M | 5M | -1M | ||||
Total Deferred Taxes | - | -296M | -578M | 901M | -1M | ||||
Normalized Net Income | -466M | 8.3B | 6B | -2.42B | -2.22B | ||||
Interest on Long-Term Debt | 9.89M | 17M | 29M | 38M | 24M | ||||
Supplemental Operating Expense Items | |||||||||
Advertising Expense | - | - | - | 204M | 146M | ||||
Selling and Marketing Expenses | - | - | - | 204M | 146M | ||||
General and Administrative Expenses | - | - | - | - | - | ||||
Research And Development Expense From Footnotes | 1.37B | 1.99B | 3.3B | 4.84B | 4.54B | ||||
Net Rental Expense, Total | 35.49M | 173M | 213M | 203M | 158M | ||||
Imputed Operating Lease Interest Expense | 15.03M | 43.21M | 46.71M | 50.52M | 30.49M | ||||
Imputed Operating Lease Depreciation | 20.46M | 130M | 166M | 152M | 128M | ||||
Stock-Based Comp., COGS (Total) | 56.16M | 90M | 138M | 194M | 289M | ||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | ||||
Stock-Based Comp., SG&A Exp. (Total) | 36.87M | 52M | 88M | 111M | 140M | ||||
Total Stock-Based Compensation | 93.02M | 142M | 226M | 305M | 429M |
- Stock Market
- Equities
- MRNA Stock
- Financials Moderna, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















